Journal of Psoriasis and Psoriatic Arthritis最新文献_第6页

Nailfold Capillaroscopy Findings in Patients With Psoriasis Vulgaris and Different Domains of Psoriatic Arthritis 寻常型银屑病患者的甲床毛细血管镜检查结果和银屑病关节炎的不同类型

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2024-03-15 DOI: 10.1177/24755303241238988

Amal M. Elmesiry, S. Mahmoud, Maha S. Mohamed, Hany Aly, Yasser A. Elmotaleb, Mohamad M. Ghit, Amira Shahin Ibrahim, S. A. Elazab, Mona Mokhtar, Eman A. Rageh, Mai A. Moussa, Sherif Ismail, Saad M. El Zokm, Hesham Hamoud

{"title":"Nailfold Capillaroscopy Findings in Patients With Psoriasis Vulgaris and Different Domains of Psoriatic Arthritis","authors":"Amal M. Elmesiry, S. Mahmoud, Maha S. Mohamed, Hany Aly, Yasser A. Elmotaleb, Mohamad M. Ghit, Amira Shahin Ibrahim, S. A. Elazab, Mona Mokhtar, Eman A. Rageh, Mai A. Moussa, Sherif Ismail, Saad M. El Zokm, Hesham Hamoud","doi":"10.1177/24755303241238988","DOIUrl":"https://doi.org/10.1177/24755303241238988","url":null,"abstract":"Psoriasis is a chronic autoimmune disease with longtime activity and multisystem affection. Nailfold capillaroscopy (NC) is a simple noninvasive microscopic tool useful for identification of nailfold microvasculopathy. The present study aimed to compare NC findings in patients with psoriasis vulgaris (PsV) and psoriatic arthritis (PsA) with different clinical domains. The present cross-sectional study included 200 psoriasis patients classified into five 40-patient groups: group I (GI) included PsA patients with predominant peripheral arthritis; group II (GII) included PsA patients with predominant peripheral arthritis and dactylitis and/or enthesitis; group III (GIII) included PsA patients with predominant axial affection; group IV (GIV) patients included PsA patients with predominant axial affection and dactylitis and/or enthesitis and group V (GV) included patients with PsV. In addition, there were 40 age and sex-matched healthy controls (GVI). The studied patients had capillary density of 6.7 ± 3.5/mm with 90 patients (45.0 %) having reduced capillary density. GI-GIV patients had significantly lower capillary density and higher frequency of patients with reduced capillary density as compared to GV patients. The reported capillary dimension in the studied patients is 15.7 ± 7.9 μm and 55 patients (27.5 %) had large/giant capillaries. Patients in GV had significantly lower capillary dimension in comparison to GI-GIV patients. There were 64 patients (32.0 %) with abnormal capillary morphology and 47 patients (23.5 %) with capillary hemorrhages. PsA patients of all domains have lower capillary density and larger capillary dimensions as compared to PsV patients.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"15 32","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140240618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review of Integrative Medical Therapies for Psoriasis: The Microbiome, Probiotics, Diet, and Mindfulness 银屑病的综合医学疗法》评论：微生物组、益生菌、饮食和心态

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2024-02-20 DOI: 10.1177/24755303241236386

Mildred Min, Ajay S Dulai, Nabeel Ahmad, Raja K Sivamani

{"title":"Review of Integrative Medical Therapies for Psoriasis: The Microbiome, Probiotics, Diet, and Mindfulness","authors":"Mildred Min, Ajay S Dulai, Nabeel Ahmad, Raja K Sivamani","doi":"10.1177/24755303241236386","DOIUrl":"https://doi.org/10.1177/24755303241236386","url":null,"abstract":"Psoriasis is a chronic inflammatory condition with cutaneous and systemic involvement. Although many efficacious treatment options are available, concerns regarding costs and duration of treatment have expanded interest in the role of integrative medical therapies for psoriasis. In this review, we aim to provide evidence for the use of integrative medical approaches in the management of psoriasis, namely approaches utilizing the microbiome, probiotics, diet, and mindfulness. PubMed/Medline and Google Scholar databases were searched from inception up to 16 August 2023 to identify clinical studies that evaluated how integrative medical therapies affect psoriasis severity. Search terms combined “psoriasis” or “psoriatic arthritis” with terms related to the microbiome, diet, and lifestyle. Multiple clinical studies have shown that integrative approaches can reduce psoriasis severity. Probiotic supplementation in psoriatic patients decreased PASI scores, decreased inflammatory markers, increased quality of life, and reduced the risk of disease relapse. Intermittent fasting, in the context of Ramadan, decreased PASI scores and plasma CRP levels. Low-calorie diets and low-calorie ketogenic diets have been shown to reduce psoriasis severity. Notably, combining low-calorie diets with biologics and cyclosporine synergistically improved psoriasis to a greater extent than pharmaceutical therapy alone. A gluten-free diet improved psoriasis and reduced antigliadin antibodies in those with hypersensitivity. Mindfulness therapies also improved psoriasis severity with and without phototherapy. Several studies show that integrative medicine can be used to manage psoriasis. Specifically, probiotic supplementation, diets that promote weight loss or modulate antigliadin antibodies, and mindfulness therapies may improve disease severity.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"56 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140445594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics of Patients With Psoriasis Treated With Various Biologics – A Danish Cohort Study 接受各种生物制剂治疗的银屑病患者的特征 - 一项丹麦队列研究

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2024-02-19 DOI: 10.1177/24755303241234292

C. W. Schwarz, L. Skov, Alexander Egeberg, A. Passey, Jennifer Lee, Patricia Gorecki, N. Loft

{"title":"Characteristics of Patients With Psoriasis Treated With Various Biologics – A Danish Cohort Study","authors":"C. W. Schwarz, L. Skov, Alexander Egeberg, A. Passey, Jennifer Lee, Patricia Gorecki, N. Loft","doi":"10.1177/24755303241234292","DOIUrl":"https://doi.org/10.1177/24755303241234292","url":null,"abstract":"Psoriasis is associated with several comorbidities and patients with psoriasis are more often obese than individuals without psoriasis. The excess disease burden is important to consider in choice of and response to treatment at the individual level. To investigate whether patient characteristics differ across biologics for patients initiating biologic therapy and for patients still on biologic therapy after 1 year. Also, to quantify and compare the use of topical therapy among patients still on biologic therapy after 1 year. This nationwide cohort study compared characteristics of patients prescribed adalimumab, etanercept, infliximab, secukinumab or ustekinumab for treatment of psoriasis by using data from the Danish registries. In the ustekinumab group, patients were younger and fewer had psoriatic arthritis. Patients treated with secukinumab and ustekinumab were less frequently co-treated with conventional systemics and topical therapy. All other patient characteristics such as sex, smoking and comorbidities other than psoriatic arthritis were similar across the biologic cohorts. These results highlight the need to better understand which factors to consider when prescribing biologics to patients with psoriasis.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"8 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139958971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Mediterranean Diet as a Potential Solution to the Gut Microbiome Dysbiosis in Psoriasis Patients 地中海饮食是解决银屑病患者肠道微生物群失调的潜在方法

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2024-01-09 DOI: 10.1177/24755303241226626

Allison Kranyak, Kathryn Haran, Payton Smith, Chandler Johnson, Wilson Liao, Tina Bhutani

{"title":"The Mediterranean Diet as a Potential Solution to the Gut Microbiome Dysbiosis in Psoriasis Patients","authors":"Allison Kranyak, Kathryn Haran, Payton Smith, Chandler Johnson, Wilson Liao, Tina Bhutani","doi":"10.1177/24755303241226626","DOIUrl":"https://doi.org/10.1177/24755303241226626","url":null,"abstract":"Adherence to a Mediterranean Diet (MeD) has been associated with lower disease severity in patients with psoriasis. However, the mechanism behind how this diet may lead to disease modification remain understudied. Recent studies have revealed dysbiosis of the gut microbiome in patients with psoriasis suggestive of inflammation and altered immune regulation. Diet affects the gut microbiome and this review aims to evaluate whether correcting this dysbiosis may be one theoretical mechanism by which the MeD may be associated with lower psoriasis severity. A literature search of the PubMed database was conducted for the terms 1) ‘psoriasis’ and ‘microbiome’ or ‘microbiota,’ and 2) ‘Mediterranean diet’ and ‘microbiome’ or ‘microbiota’ with manual screening for relevant articles. In total, we identified 9 relevant primary research studies investigating the gut microbiome in patients with psoriasis and 16 relevant primary research studies investigating changes in the microbiota for those consuming a MeD. Though varying in exact levels of certain bacteria, studies analyzing the microbiome in psoriasis revealed dysbiosis. Those analyzing the effect of the Mediterranean diet on the microbiome revealed beneficial changes, including alleviating some of the same alterations seen in the microbiome of those with psoriasis. Microbiota change is a possible mechanism why the MeD has previously been associated with lower psoriasis severity.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"49 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139442156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comorbidity Burden in Psoriasis Patients with Skin of Color. 有色皮肤银屑病患者的共病负担

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2024-01-01 Epub Date: 2023-08-29 DOI: 10.1177/24755303231198482

Hannah Peterson, Margaret Y Huang, Kathryn Lee, Paige Kingston, Danielle Yee, Edwin Korouri, Rosario Agüero, April W Armstrong

{"title":"Comorbidity Burden in Psoriasis Patients with Skin of Color.","authors":"Hannah Peterson, Margaret Y Huang, Kathryn Lee, Paige Kingston, Danielle Yee, Edwin Korouri, Rosario Agüero, April W Armstrong","doi":"10.1177/24755303231198482","DOIUrl":"10.1177/24755303231198482","url":null,"abstract":"Background: Psoriasis is a chronic disease with increased risk of numerous comorbidities. Known differences exist regarding treatment outcomes for psoriasis patients with skin of color (SOC). However, factors contributing to these differences are relatively unknown.Objectives: This study aims to compare the comorbidity burden in SOC psoriasis patients vs. White patients, as measured by the Charlson Comorbidity Index (CCI) score.Methods: We utilized the National Ambulatory Medical Care Survey (NAMCS) to identify visits for adult psoriasis patients occurring in the years 2002-2016 and 2018. The CCI was used to objectively measure comorbidity burden. Patients were identified by race, and SOC was defined as any reported race besides White Only. A multiple linear regression was run to compare the CCI among adult psoriasis patients based on race and ethnicity, controlling for age, sex, insurance status, and geographic region.Results: A total of 39,176,928 weighted visits were analyzed. Compared to White patients, patients with SOC did not have statistically significant differences in comorbidity burden, as measured by CCI score (p=0.073 for Black/African American Only vs. White Only, p=0.073 for American Indian/Alaska Native Only vs. White Only, p=0.435 for Asian Only vs. White Only, p=0.403 for Native Hawaiian/Pacific Islander Only vs. White Only, p=0.195 for Other vs. White Only).Conclusion: Patients with SOC were not found to have differences in comorbidity burden compared to White patients. These results highlight that social factors such as socioeconomic status and access to healthcare may contribute more directly to psoriasis treatment outcomes than patient race.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"16-22"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10957134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44279585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data 银屑病治疗升级的相关因素：电子健康记录数据分析

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-12-07 DOI: 10.1177/24755303231212870

Jamie L. W. Rhoads, W. Malatestinic, Russel Burge, Michael L. Ganz, K. Duffin

{"title":"Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data","authors":"Jamie L. W. Rhoads, W. Malatestinic, Russel Burge, Michael L. Ganz, K. Duffin","doi":"10.1177/24755303231212870","DOIUrl":"https://doi.org/10.1177/24755303231212870","url":null,"abstract":"Electronic health records (EHRs) offer the possibility of using data entry templates to simultaneously document routine clinical care and capture disease-specific measures as discrete data elements that can be used for health services research (HSR). The objective of this study was to determine factors associated with meaningful treatment escalation (MTE) of psoriasis as a pilot study for future real-world HSR studies. We conducted a retrospective, observational cohort study of psoriasis patients by using data collected during routine clinical care from an EHR using EpiCare® SmartForms. The psoriasis SmartForm records psoriasis disease severity measures and descriptive findings to generate visit notes. These data were extracted and analyzed to identify factors associated with MTE, defined as changing or adding, phototherapy, systemic, or biologic therapy. 473 psoriasis patients met study criteria; 239 underwent MTE between their first and third observed visits. Patients who experienced MTE had more severe disease at Visit 1—assessed by BSA, pPGA, oPGA, and a patient-reported disease severity measure--than patients who did not experience MTE. Other factors associated with MTE included use of topicals only or no active treatment at Visit 1, palmoplantar disease, and involvement of other difficult-to-treat body areas. Patients who underwent MTE experienced larger improvements in disease severity than those who did not. This study highlights how data collected during routine clinical practice can be readily used for real-world retrospective HSR when disease measures are captured as discrete elements. This approach could provide a cost-effective platform to conduct real-world HSR.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"48 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138593955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predicting Psoriatic Arthritis in Psoriasis Patients – A Swiss Registry Study 预测银屑病患者的银屑病关节炎--一项瑞士登记研究

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-11-21 DOI: 10.1177/24755303231217492

Mia‐Louise Nielsen, T. Petersen, L. V. Maul, J. P. Thyssen, S. F. Thomsen, Jashin J. Wu, A. A. Navarini, Thomas Kündig, Nikhil Yawalkar, Christoph Schlapbach, Wolf-Henning Boehncke, Curdin Conrad, Antonio Cozzio, R. Micheroli, Lars Erik Kristensen, Alexander Egeberg, J. Maul

{"title":"Predicting Psoriatic Arthritis in Psoriasis Patients – A Swiss Registry Study","authors":"Mia‐Louise Nielsen, T. Petersen, L. V. Maul, J. P. Thyssen, S. F. Thomsen, Jashin J. Wu, A. A. Navarini, Thomas Kündig, Nikhil Yawalkar, Christoph Schlapbach, Wolf-Henning Boehncke, Curdin Conrad, Antonio Cozzio, R. Micheroli, Lars Erik Kristensen, Alexander Egeberg, J. Maul","doi":"10.1177/24755303231217492","DOIUrl":"https://doi.org/10.1177/24755303231217492","url":null,"abstract":"Psoriatic arthritis (PsA) is a prevalent comorbidity among patients with psoriasis, heavily contributing to their burden of disease, usually diagnosed several years after the diagnosis of psoriasis. To investigate the predictability of psoriatic arthritis in patients with psoriasis and to identify important predictors. Data from the Swiss Dermatology Network on Targeted Therapies (SDNTT) involving patients treated for psoriasis were utilized. A combination of gradient-boosted decision trees and mixed models was used to classify patients based on their diagnosis of PsA or its absence. The variables with the highest predictive power were identified. Time to PsA diagnosis was visualized with the Kaplan-Meier method and the relationship between severity of psoriasis and PsA was explored through quantile regression. A diagnosis of psoriatic arthritis was registered at baseline of 407 (29.5%) treatment series. 516 patients had no registration of PsA, 257 patients had PsA at inclusion, and 91 patients were diagnosed with PsA after inclusion. The model’s AUROCs was up to 73.7%, and variables with the highest discriminatory power were age, PASI, physical well-being, and severity of nail psoriasis. Among patients who developed PsA after inclusion, significantly more first treatment series were classified in the PsA-group, compared to those with no PsA registration. PASI was significantly correlated with the median burden/severity of PsA ( P = .01). Distinguishing between patients with and without PsA based on clinical characteristics is feasible and even predicting future diagnoses of PsA is possible. Patients at higher risk can be identified using important predictors of PsA.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"28 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139252862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing Comparative Efficacy of Biologics for the Treatment of Psoriasis With Nail Involvement: A Systematic Review 评估生物制剂治疗指甲受累型银屑病的比较疗效：系统回顾

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-11-18 DOI: 10.1177/24755303231217491

Madiha Khan, Carly E. Wallace, Fahad Ahmed, Syed Minhaj Rahman, Nashwah Memon, Adel Haque

{"title":"Assessing Comparative Efficacy of Biologics for the Treatment of Psoriasis With Nail Involvement: A Systematic Review","authors":"Madiha Khan, Carly E. Wallace, Fahad Ahmed, Syed Minhaj Rahman, Nashwah Memon, Adel Haque","doi":"10.1177/24755303231217491","DOIUrl":"https://doi.org/10.1177/24755303231217491","url":null,"abstract":"Despite recent advances in biologics, there is a lack of significant evidence regarding the comparative efficacy of biologics in treating more resistant features of psoriasis, namely nail psoriasis. A systematic review synthesizing data from multiple studies is efficacious in assessing the comparative efficacy among biologics for the treatment of nail psoriasis. To evaluate and compare the efficacy of biologics for the treatment of nail psoriasis. Utilizing PRISMA guidelines, a systematic literature review was conducted using the Pubmed database on November 16, 2022. Studies selected were phase 3 or 4 randomized clinical trials, clinical studies, or other randomized trials with data on the treatment with biologics for adults with nail psoriasis. Sixteen studies meeting inclusion criteria were included for analysis. At 24 weeks, the highest mean NAPSI percent improvement achieved at week 24 was by brodalumab (76.9%) followed by etanercept (74%) and ixekizumab (70.5%) while the biologics achieving the greatest proportion of NAPSI 0 were adalimumab (44.6%) and ixekizumab (41%). This study helps elucidate the comparative efficacy of biologics for the treatment of nail psoriasis. This review suggests that brodalumab and etanercept are associated with the highest percent improvement in nail psoriasis while adalimumab and ixekizumab are associated with the greatest probability of complete nail resolution.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"177 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139261323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biosimilars in Dermatology Review 皮肤病学综述中的生物仿制药

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-11-03 DOI: 10.1177/24755303231212154

John Baker, Robert Kalb

{"title":"Biosimilars in Dermatology Review","authors":"John Baker, Robert Kalb","doi":"10.1177/24755303231212154","DOIUrl":"https://doi.org/10.1177/24755303231212154","url":null,"abstract":"Background Safe and effective biosimilar medications have the potential to significantly increase access to these valuable drugs. The two current biosimilars available in dermatology in the United States (US) are infliximab and rituximab which were Food and Drug Administration (FDA) approved in 2016 and 2018 respectively. There has been significant interest in this topic as a number of biosimilar versions of adalimumab will be available in 2023. Objective This review will discuss biosimilar basics and the experience with biosimilars used in dermatology in the US, Asia, and Europe. Methods All articles in Ovid/Medline from 2015 to Feb 2023 on biosimilars were reviewed with a particular emphasis on medications used in dermatology. Other reports from pharmaceutical manufacturers and blogs following the development of the biosimilar industry provided key insights. Results Biosimilars have been able to produce significant savings and market share increases, particularly in Europe, where there has been a longer experience. The specifics depend on drug prescribing practices and incentives in the individual country. This degree of savings and market share increases have not been realized with the current biosimilars available in the US. Conclusion While biosimilars have resulted in significant savings compared to originator drugs, it is clear that prescribing incentives and physician education are crucial in achieving these savings. To what degree biosimilar market share will increase in the US remains to be determined.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"6 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135869241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Influence of Psoriasis on Type 2 Diabetes Mellitus Patient Profiles: A National Inpatient Sample Study 银屑病对2型糖尿病患者的影响:一项全国住院患者样本研究

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-11-02 DOI: 10.1177/24755303231212153

Nilesh Kodali, Isabella Blanchard, Keshav D. Kumar, Mallory Zaino, Steven R. Feldman

{"title":"The Influence of Psoriasis on Type 2 Diabetes Mellitus Patient Profiles: A National Inpatient Sample Study","authors":"Nilesh Kodali, Isabella Blanchard, Keshav D. Kumar, Mallory Zaino, Steven R. Feldman","doi":"10.1177/24755303231212153","DOIUrl":"https://doi.org/10.1177/24755303231212153","url":null,"abstract":"Background Psoriasis is believed to be a common comorbidity of type 2 diabetes mellitus (T2DM). Little is known on the impact psoriasis has on T2DM patients’ disease profiles. Objective To assess the impact psoriasis has on T2DM patients’ demographics, comorbidities, and health care outcomes. Methods We retrospectively analyzed the 2017 U.S. National Inpatient Sample (NIS) database. We utilized ICD-10 codes to determine T2DM and psoriasis patients along with associated comorbidities. Continuous variables were compared by independent-sample t-tests and categorical variables were compared via Pearson chi-square. All analysis were conducted in IBM SPSS 25. Results Among 7,705,988 T2DM admissions, 0.67% of them had comorbid psoriasis. T2DM psoriasis patients (64.38; SD: 12.403) were, on average, younger (64.38 vs 66.73; P < .001) and white (78.7% vs 63.1%; P < .001) and had increased foot ulcers (4.2% vs 3.8%; P < .001), hyperglycemia (22.4% vs 21.0%; P < .001), retinopathy (22.4% vs 21.0%; P < .001), hypercoagulopathy (8.5% vs 6.9%; P < .001), and hypertension (72.5% vs 70.4%; P < .001) than T2DM patients without psoriasis. T2DM psoriasis patients spent more days in the hospital (5.49 vs 5.37; P < .001), had more concurrent diagnoses (19.05 vs 16.5; P < .001), less total charges ($60,596.71 vs $61,534.66; P = 0.010) and had less in-hospital deaths (2.0% vs 2.7%; P < .001) than T2DM patients without psoriasis. Conclusions The presence of comorbid psoriasis significantly impacts T2DM patients’ demographics, comorbidities, and health care outcomes. These findings underscore the importance of early disease monitoring, cross-specialty collaboration, and medication monitoring in order to guide individualized management strategies and optimize patient care.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"12 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135974535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0